Acimmune SA logo

Acimmune SA (ACIU)

Market Closed
22 Jul, 16:56
NASDAQ (NMS) NASDAQ (NMS)
$
2. 18
+0.1
+4.81%
$
205.8M Market Cap
- P/E Ratio
0% Div Yield
2,085 Volume
-0.49 Eps
$ 2.08
Previous Close
Day Range
2.15 2.19
Year Range
1.43 4.26
Want to track ACIU and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 13 days

Summary

ACIU closed today higher at $2.18, an increase of 4.81% from yesterday's close, completing a monthly increase of 7.39% or $0.15. Over the past 12 months, ACIU stock lost -19.26%.
ACIU is not paying dividends to its shareholders.
The last earnings report, released on May 12, 2025, exceeded the consensus estimates by 0.02%. On average, the company has surpassed earnings expectations by 0.11%, based on the last three reports. The next scheduled earnings report is due on Aug 05, 2025.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on NASDAQ (NMS) (USD).

ACIU Chart

Chart

Chart with 60 data points.
The chart has 1 X axis displaying categories.
The chart has 2 Y axes displaying values, and values.
End of interactive chart.
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates

AC Immune (ACIU) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.21 per share a year ago.

Zacks | 2 months ago
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold?

AC Immune's shares decline 18.3% in a month. While the company's pipeline progress is encouraging, we advise investors to remain on the sidelines for now.

Zacks | 4 months ago
AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

AC Immune (ACIU) Upgraded to Strong Buy: Here's What You Should Know

AC Immune (ACIU) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 4 months ago

Acimmune SA Dividends

ACIU is not paying dividends to its shareholders.

Acimmune SA Earnings

6 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
12 May 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
1 Nov 2024 Date
-
Cons. EPS
0.06
EPS
ACIU is not paying dividends to its shareholders.
6 Aug 2025 (In 2 weeks) Date
-
Cons. EPS
-
EPS
5 Aug 2025 (In 1 week) Date
-
Cons. EPS
-
EPS
12 May 2025 Date
-
Cons. EPS
-
EPS
12 Mar 2025 Date
-
Cons. EPS
-
EPS
1 Nov 2024 Date
-
Cons. EPS
0.06
EPS

Acimmune SA (ACIU) FAQ

What is the stock price today?

The current price is $2.18.

On which exchange is it traded?

Acimmune SA is listed on NASDAQ (NMS).

What is its stock symbol?

The ticker symbol is ACIU.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 0%.

What is its market cap?

As of today, the market cap is 205.8M.

When is the next earnings date?

The next earnings report will release on Aug 05, 2025.

Has Acimmune SA ever had a stock split?

No, there has never been a stock split.

Acimmune SA Profile

Biotechnology Industry
Healthcare Sector
Andrea Pfeifer CEO
NASDAQ (NMS) Exchange
H00263105 Cusip
CH Country
133 Employees
- Last Dividend
- Last Split
23 Sep 2016 IPO Date

Overview

AC Immune SA is a clinical stage biopharmaceutical company engaged in the discovery, design, and development of therapeutic and diagnostic products aimed at combating neurodegenerative diseases caused by protein misfolding. Utilizing its proprietary SupraAntigen and Morphomer platforms, the company focuses on creating vaccines, antibodies, and small molecules that specifically target misfolded proteins associated with various neurodegenerative conditions. Through collaborations with leading pharmaceutical entities and its innovative research in the field, AC Immune SA seeks to address the unmet needs in the treatment and diagnosis of these complex diseases. Founded in 2003, the company is based in Lausanne, Switzerland, showcasing its global reach and commitment to improving patients' lives affected by neurodegenerative diseases.

Products and Services

  • Crenezumab

    This humanized, conformation-specific monoclonal antibody is in Phase II clinical trial stage, targeting the treatment of Alzheimer's disease (AD). Crenezumab showcases AC Immune’s focus on addressing the critical need for effective treatments against AD.

  • ACI-24

    An anti-Abeta vaccine candidate currently in Phase II clinical study for Alzheimer's disease, and has completed Phase Ib for Down syndrome. ACI-24 demonstrates the company’s innovative approach to vaccine development for neurodegenerative diseases.

  • ACI-35

    This anti-Tau vaccine candidate is undergoing Phase Ib/2a clinical study, emphasizing the company's dedication to targeting Tau pathology in neurodegenerative disorders, particularly Alzheimer's disease.

  • Tau-positron emission tomography (PET) imaging tracer

    Currently in Phase II clinical study, this diagnostic tool represents AC Immune’s commitment to advancing Alzheimer's disease diagnostics by improving the detection of Tau pathology in patients.

  • Small Molecule Tau Aggregation Inhibitors

    These compounds are being researched and developed for Alzheimer's disease and NeuroOrphan indications, showcasing AC Immune’s efforts in creating targeted treatments for a range of neurodegenerative conditions through small molecule therapeutics.

  • Discovery and Preclinical Stage Molecules

    Focusing on a range of neurodegenerative diseases, these molecules are under exploration for the development of diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. This effort reflects the company's comprehensive approach to tackle the various aspects of neurodegenerative diseases beyond Alzheimer's.

Contact Information

Address: Building B
Phone: 41 21 345 91 21